Axon Enterprise (NASDAQ:AXON) Insider Elizabeth Reid Coughlin Sells 1,554 Shares

Axon Enterprise, Inc (NASDAQ:AXON) insider Elizabeth Reid Coughlin sold 1,554 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $485.00, for a total value of $753,690.00. Following the completion of the transaction, the insider directly owned 34,024 shares of the company’s stock, valued at approximately $16,501,640. The trade was a 4.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Axon Enterprise Stock Down 3.1%

Shares of AXON traded down $15.06 during trading hours on Monday, hitting $471.06. The company had a trading volume of 941,797 shares, compared to its average volume of 1,098,205. The company’s fifty day moving average price is $408.04 and its two-hundred day moving average price is $491.56. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $885.91. The company has a market capitalization of $37.97 billion, a PE ratio of 189.18, a price-to-earnings-growth ratio of 8.84 and a beta of 1.45. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The company had revenue of $807.35 million for the quarter, compared to analyst estimates of $778.91 million. During the same period in the prior year, the company posted $1.47 EPS. The firm’s quarterly revenue was up 33.7% compared to the same quarter last year. As a group, equities analysts forecast that Axon Enterprise, Inc will post 1.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on AXON shares. Morgan Stanley set a $600.00 target price on Axon Enterprise in a research report on Thursday, May 7th. UBS Group reduced their target price on Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. Zacks Research raised Axon Enterprise from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Barclays reduced their target price on Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, Citigroup reaffirmed a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $712.75.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of AXON. Baillie Gifford & Co. increased its holdings in shares of Axon Enterprise by 1,198.7% in the fourth quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after purchasing an additional 1,516,099 shares during the period. Edgewood Management LLC acquired a new position in shares of Axon Enterprise in the fourth quarter valued at about $846,516,000. Wellington Management Group LLP increased its holdings in shares of Axon Enterprise by 326.9% in the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after purchasing an additional 1,179,038 shares during the period. Norges Bank acquired a new position in shares of Axon Enterprise in the fourth quarter valued at about $515,764,000. Finally, Vanguard Group Inc. increased its holdings in shares of Axon Enterprise by 4.2% in the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after purchasing an additional 376,904 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.